MAYFIELD MEDICAL PROPERTIES LIMITED


2020-01-012020-12-312020-12-31false04413846MAYFIELD MEDICAL PROPERTIES LIMITED2021-09-22iso4217:GBPxbrli:pure044138462020-01-01044138462020-12-31044138462020-01-012020-12-31044138462019-01-01044138462019-12-31044138462019-01-012019-12-3104413846bus:SmallEntities2020-01-012020-12-3104413846bus:AuditExempt-NoAccountantsReport2020-01-012020-12-3104413846bus:FullAccounts2020-01-012020-12-3104413846bus:PrivateLimitedCompanyLtd2020-01-012020-12-3104413846core:WithinOneYear2020-12-3104413846core:AfterOneYear2020-12-3104413846core:WithinOneYear2019-12-3104413846core:AfterOneYear2019-12-310441384612020-01-012020-12-3104413846core:ShareCapital2020-12-3104413846core:SharePremium2020-12-3104413846core:RevaluationReserve2020-12-3104413846core:OtherReservesSubtotal2020-12-3104413846core:RetainedEarningsAccumulatedLosses2020-12-3104413846core:ShareCapital2019-12-3104413846core:SharePremium2019-12-3104413846core:RevaluationReserve2019-12-3104413846core:OtherReservesSubtotal2019-12-3104413846core:RetainedEarningsAccumulatedLosses2019-12-3104413846core:LandBuildings2020-12-3104413846core:PlantMachinery2020-12-3104413846core:Vehicles2020-12-3104413846core:FurnitureFittings2020-12-3104413846core:OfficeEquipment2020-12-3104413846core:NetGoodwill2020-12-3104413846core:IntangibleAssetsOtherThanGoodwill2020-12-3104413846core:ListedExchangeTraded2020-12-3104413846core:UnlistedNon-exchangeTraded2020-12-3104413846core:LandBuildings2019-12-3104413846core:PlantMachinery2019-12-3104413846core:Vehicles2019-12-3104413846core:FurnitureFittings2019-12-3104413846core:OfficeEquipment2019-12-3104413846core:NetGoodwill2019-12-3104413846core:IntangibleAssetsOtherThanGoodwill2019-12-3104413846core:ListedExchangeTraded2019-12-3104413846core:UnlistedNon-exchangeTraded2019-12-3104413846core:LandBuildings2020-01-012020-12-3104413846core:PlantMachinery2020-01-012020-12-3104413846core:Vehicles2020-01-012020-12-3104413846core:FurnitureFittings2020-01-012020-12-3104413846core:OfficeEquipment2020-01-012020-12-3104413846core:NetGoodwill2020-01-012020-12-3104413846core:IntangibleAssetsOtherThanGoodwill2020-01-012020-12-3104413846core:ListedExchangeTraded2020-01-012020-12-3104413846core:UnlistedNon-exchangeTraded2020-01-012020-12-3104413846core:MoreThanFiveYears2020-01-012020-12-3104413846core:Non-currentFinancialInstruments2020-12-3104413846core:Non-currentFinancialInstruments2019-12-3104413846dpl:CostSales2020-01-012020-12-3104413846dpl:DistributionCosts2020-01-012020-12-3104413846dpl:AdministrativeExpenses2020-01-012020-12-3104413846core:LandBuildings2020-01-012020-12-3104413846core:PlantMachinery2020-01-012020-12-3104413846core:Vehicles2020-01-012020-12-3104413846core:FurnitureFittings2020-01-012020-12-3104413846core:OfficeEquipment2020-01-012020-12-3104413846core:NetGoodwill2020-01-012020-12-3104413846core:IntangibleAssetsOtherThanGoodwill2020-01-012020-12-3104413846dpl:GroupUndertakings2020-01-012020-12-3104413846dpl:ParticipatingInterests2020-01-012020-12-3104413846dpl:GroupUndertakingscore:ListedExchangeTraded2020-01-012020-12-3104413846core:ListedExchangeTraded2020-01-012020-12-3104413846dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2020-01-012020-12-3104413846core:UnlistedNon-exchangeTraded2020-01-012020-12-3104413846dpl:CostSales2019-01-012019-12-3104413846dpl:DistributionCosts2019-01-012019-12-3104413846dpl:AdministrativeExpenses2019-01-012019-12-3104413846core:LandBuildings2019-01-012019-12-3104413846core:PlantMachinery2019-01-012019-12-3104413846core:Vehicles2019-01-012019-12-3104413846core:FurnitureFittings2019-01-012019-12-3104413846core:OfficeEquipment2019-01-012019-12-3104413846core:NetGoodwill2019-01-012019-12-3104413846core:IntangibleAssetsOtherThanGoodwill2019-01-012019-12-3104413846dpl:GroupUndertakings2019-01-012019-12-3104413846dpl:ParticipatingInterests2019-01-012019-12-3104413846dpl:GroupUndertakingscore:ListedExchangeTraded2019-01-012019-12-3104413846core:ListedExchangeTraded2019-01-012019-12-3104413846dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2019-01-012019-12-3104413846core:UnlistedNon-exchangeTraded2019-01-012019-12-3104413846core:NetGoodwill2020-12-3104413846core:IntangibleAssetsOtherThanGoodwill2020-12-3104413846core:LandBuildings2020-12-3104413846core:PlantMachinery2020-12-3104413846core:Vehicles2020-12-3104413846core:FurnitureFittings2020-12-3104413846core:OfficeEquipment2020-12-3104413846core:AfterOneYear2020-12-3104413846core:WithinOneYear2020-12-3104413846core:ListedExchangeTraded2020-12-3104413846core:UnlistedNon-exchangeTraded2020-12-3104413846core:ShareCapital2020-12-3104413846core:SharePremium2020-12-3104413846core:RevaluationReserve2020-12-3104413846core:OtherReservesSubtotal2020-12-3104413846core:RetainedEarningsAccumulatedLosses2020-12-3104413846core:NetGoodwill2019-12-3104413846core:IntangibleAssetsOtherThanGoodwill2019-12-3104413846core:LandBuildings2019-12-3104413846core:PlantMachinery2019-12-3104413846core:Vehicles2019-12-3104413846core:FurnitureFittings2019-12-3104413846core:OfficeEquipment2019-12-3104413846core:AfterOneYear2019-12-3104413846core:WithinOneYear2019-12-3104413846core:ListedExchangeTraded2019-12-3104413846core:UnlistedNon-exchangeTraded2019-12-3104413846core:ShareCapital2019-12-3104413846core:SharePremium2019-12-3104413846core:RevaluationReserve2019-12-3104413846core:OtherReservesSubtotal2019-12-3104413846core:RetainedEarningsAccumulatedLosses2019-12-3104413846core:NetGoodwill2019-01-0104413846core:IntangibleAssetsOtherThanGoodwill2019-01-0104413846core:LandBuildings2019-01-0104413846core:PlantMachinery2019-01-0104413846core:Vehicles2019-01-0104413846core:FurnitureFittings2019-01-0104413846core:OfficeEquipment2019-01-0104413846core:AfterOneYear2019-01-0104413846core:WithinOneYear2019-01-0104413846core:ListedExchangeTraded2019-01-0104413846core:UnlistedNon-exchangeTraded2019-01-0104413846core:ShareCapital2019-01-0104413846core:SharePremium2019-01-0104413846core:RevaluationReserve2019-01-0104413846core:OtherReservesSubtotal2019-01-0104413846core:RetainedEarningsAccumulatedLosses2019-01-0104413846core:AfterOneYear2020-01-012020-12-3104413846core:WithinOneYear2020-01-012020-12-3104413846core:Non-currentFinancialInstrumentscore:CostValuation2020-01-012020-12-3104413846core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2020-01-012020-12-3104413846core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2020-01-012020-12-3104413846core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2020-01-012020-12-3104413846core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2020-01-012020-12-3104413846core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2020-01-012020-12-3104413846core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2020-01-012020-12-3104413846core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2020-01-012020-12-3104413846core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2020-01-012020-12-3104413846core:Non-currentFinancialInstrumentscore:CostValuation2020-12-3104413846core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2020-12-3104413846core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2020-12-3104413846core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2020-12-3104413846core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2020-12-3104413846core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2020-12-3104413846core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2020-12-3104413846core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2020-12-3104413846core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2020-12-3104413846core:Non-currentFinancialInstrumentscore:CostValuation2019-12-3104413846core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2019-12-3104413846core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2019-12-3104413846core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2019-12-3104413846core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2019-12-3104413846core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2019-12-3104413846core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2019-12-3104413846core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2019-12-3104413846core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2019-12-3104413846bus:Director12020-01-012020-12-3104413846bus:Director22020-01-012020-12-3104413846bus:Director32020-01-012020-12-3104413846bus:Director42020-01-012020-12-3104413846core:FurnitureFittingsToolsEquipment2019-12-3104413846core:FurnitureFittingsToolsEquipment2020-01-012020-12-3104413846core:FurnitureFittingsToolsEquipment2020-12-31

MAYFIELD MEDICAL PROPERTIES LIMITED

(formerly PREMIER MEDICAL PROPERTIES LIMITED)

Registered Number
04413846
(England and Wales)

Unaudited Financial Statements for the Year Ended
31 December 2020

MAYFIELD MEDICAL PROPERTIES LIMITED
Company Information
for the year from 1 January 2020 to 31 December 2020

Directors

Kewal Krishan
Parkash Krishan
Sandeep Krishan
Sukhdeep Krishan

Registered Address

7 Bell Yard
London
WC2A 2JR

Registered Number

04413846 (England and Wales)
MAYFIELD MEDICAL PROPERTIES LIMITED
Balance Sheet as at
31 December 2020

Notes

2020

2019

£

£

£

£

Fixed assets
Tangible assets72,335,4792,336,535
2,335,4792,336,535
Current assets
Debtors1133,653123,663
Cash at bank and on hand19,2683,174
52,921126,837
Creditors amounts falling due within one year12(391,640)(346,381)
Net current assets (liabilities)(338,719)(219,544)
Total assets less current liabilities1,996,7602,116,991
Creditors amounts falling due after one year13(630,000)(735,000)
Provisions for liabilities14(128,601)(133,611)
Net assets1,238,1591,248,380
Capital and reserves
Called up share capital100100
Other reserves548,248550,896
Profit and loss account689,811697,384
Shareholders' funds1,238,1591,248,380
  • The company was entitled to exemption from audit for this reporting period under section 477 of the Companies Act 2006 relating to small companies.
  • The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.
  • The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.
  • These accounts have been prepared in accordance with the provisions applicable to companies subject to the small companies regime. The directors have chosen to not file a copy of the company’s profit and loss account.
The financial statements were approved and authorised for issue by the Board of Directors on 22 September 2021, and are signed on its behalf by:
Sandeep Krishan
Director
Registered Company No. 04413846
MAYFIELD MEDICAL PROPERTIES LIMITED
Notes to the Financial Statements
for the year ended 31 December 2020

1.STATUTORY INFORMATION
Mayfield Medical Properties Limited is a private company, limited by shares, registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page. The presentation currency of the financial statements is the Pound Sterling (£).
2.COMPLIANCE WITH APPLICABLE REPORTING FRAMEWORK
The financial statements have been prepared in accordance with Financial Reporting Standard 102, "The Financial Reporting Standard applicable in the UK and Republic of Ireland", including the provisions of Section 1A, "Small Entities", and the Companies Act 2006.
3.PRINCIPAL ACTIVITIES
The principal activity of the company in the year under review was that of letting and operating of own or leased real estate.
4.BASIS OF MEASUREMENT USED IN FINANCIAL STATEMENTS
The financial statements have been prepared under the historical cost convention.
5.ACCOUNTING POLICIES
Turnover policy
Turnover is measured at the fair value of the consideration received or receivable from the sale of services, net of discounts, rebates, value added tax and other sales taxes.
Property, plant and equipment policy
Land and buildings are initially recognised at cost, which includes purchase cost and any directly attributable expenditure. Land and buildings whose fair value can be measured reliably are measured at fair value. The surplus or deficit on revaluation is recognised in the profit and loss account, then accumulated in an other reserve, unless a deficit below original cost, or its reversal, on an individual plot of land or building is expected to be permanent, in which case it is recognised in the profit and loss account for the year. Other tangible fixed assets are stated at cost (or deemed cost) or valuation less accumulated depreciation and accumulated impairment losses. Cost includes costs directly attributable to bringing the asset to the location and condition necessary for it to be capable of operating in the manner intended by management. Depreciation is charged so as to allocate the cost of assets less their residual value over their estimated useful lives, using either a straight line or reducing balance method, as indicated below. Depreciation is provided on the following basis: Fixtures and fittings - 5 years straight line The assets' residual values, useful lives and depreciation methods are reviewed and adjusted prospectively if appropriate or if there is an indication of a significant change since the last reporting date. Gains and losses on disposals are determined by comparing the proceeds with the carrying amount and are recognised in profit or loss.
Revenue recognition policy
Turnover from the rendering of services is recognised in the period in which the services are provided, in accordance with the stage of completion of the contract, and when all of the following conditions are satisfied: - the amount of revenue can be measured reliably; - it is probable that the company will receive the consideration due under the contract; - the stage of completion of the contract at the end of the reporting period can be measured reliably; and, - the costs incurred and the costs to complete the contract can be measured reliably.
Deferred tax policy
Deferred tax is recognised in respect of all timing differences between the recognition of income and expenses in the financial statements and their inclusion in tax assessments. Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Deferred tax is measured using the tax rates and laws that have been enacted or substantively enacted by the reporting date and that are expected to apply to the reversal of the timing difference, except for revalued land and investment property where the tax rate that applies to the sale of the asset is used. Current and deferred tax assets and liabilities are not discounted.
Valuation of financial instruments policy
Debtors and creditors with no stated interest rate and receivable or payable within one year are recorded at transaction price. Any losses arising from impairment are recognised immediately in profit or loss.
Going concern
At the year end, the company had net current liabilities of £338,719 (2019: £219,544); however, the directors have confirmed that they will support the company for the foreseeable future. Furthermore, the directors do not anticipate that the ongoing Covid-19 pandemic will affect the company's ability to continue for the foreseeable future, given the avenues of support that are available. As such, the company continues to adopt the going concern basis in preparing its financial statements.
6.EMPLOYEE INFORMATION




2020



2019

Average number of employees during the year--
7.PROPERTY, PLANT AND EQUIPMENT



Land & buildings
£


Fixtures & fittings
£


Total
£

Cost or valuation
At 01 January 202,335,00037,9422,372,942
Additions3,270-3,270
Revaluations(3,270)-(3,270)
At 31 December 202,335,00037,9422,372,942
Depreciation and impairment
At 01 January 20-36,40736,407
Charge for year-1,0561,056
At 31 December 20-37,46337,463
Net book value
At 31 December 202,335,0004792,335,479
At 31 December 192,335,0001,5352,336,535
8.REVALUATION OF PROPERTY, PLANT AND EQUIPMENT
Valuation of land and buildings at 31 December 2020 is represented by: Valuation in 2007 - £612,329 Valuation in 2018 - £67,790 Valuation in 2020 - (£3,270) Cost - £1,658,151 Total - £2,335,000
9.DESCRIPTION OF NATURE OF TRANSACTIONS AND BALANCES WITH RELATED PARTIES
At the year end, a balance of £55,524 (2019: £69,322) was owed to company of which Kewal Krishan, Parkash Krishan and Sukhdeep Krishan are directors. Sales totalling £31,832 (2019: £31,832) were made to this company during the year. At the year end, a balance of £51,534 was owed to (2019: £122,097 was owed by) a partnership in which Kewal Krishan, Parkash Krishan and Sukhdeep Krishan are partners. Sales totalling £94,300 (2019: £94,300) were made to this partnership during the year.
10.FURTHER INFORMATION REGARDING THE COMPANY'S FINANCIAL POSITION
Bank borrowings and overdrafts are comprised by a £735,000 bank loan (2019: £840,000). This bank loan is covered by both a fixed and floating charge with Handelsbanken PLC. The floating charge covers all the property or undertaking of the company.
11.DEBTORS
Basic financial assets, including trade and other debtors, are initially recognised at transaction price, unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Such assets are subsequently carried at amortised cost using the effective interest method, less any impairment.



2020
£


2019
£

Other debtors33,653122,097
Prepayments and accrued income-1,566
Total33,653123,663
12.CREDITORS WITHIN ONE YEAR
Basic financial liabilities, including trade and other creditors, loans from third parties and loans from related parties, are initially recognised at transaction price, unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest. Such instruments are subsequently carried at amortised cost using the effective interest method, less any impairment.



2020
£


2019
£

Trade creditors / trade payables8,54315,677
Bank borrowings and overdrafts105,000105,000
Taxation and social security142,58765,803
Other creditors121,970124,878
Accrued liabilities and deferred income13,54035,023
Total391,640346,381
13.CREDITORS AFTER ONE YEAR



2020
£


2019
£

Bank borrowings and overdrafts630,000735,000
Total630,000735,000
14.PROVISIONS FOR LIABILITIES



2020
£


2019
£

Net deferred tax liability (asset)128,601133,611
Total128,601133,611